Core Insights - CME Group has launched XRP futures, marking a significant addition to its cryptocurrency offerings, with the first trade occurring on May 18, 2025 [1][2] - The initial trading day saw over $19 million in notional volume, indicating strong early interest in the new futures contracts [2] Product Details - XRP futures are available in two contract sizes: a micro-sized contract of 2,500 XRP and a larger contract of 50,000 XRP [2] - These contracts are cash-settled based on the CME CF XRP-Dollar Reference Rate, which is calculated daily at 4:00 p.m. London time [2] Institutional Adoption - The launch of XRP futures is seen as a milestone for institutional adoption of digital assets, enhancing liquidity and risk management capabilities around XRP [2] - Hidden Road, a significant player in the non-bank prime brokerage space, expressed excitement about the first block trade and its implications for market access and innovation in digital assets [2]

Group 1 - CME Group is one of 858 individual stocks in the Finance sector and is ranked 6 in the Zacks Sector Rank [2] - CME Group currently has a Zacks Rank of 2 (Buy), indicating a favorable outlook for the stock [3] - The Zacks Consensus Estimate for CME's full-year earnings has increased by 6.9% in the past quarter, reflecting stronger analyst sentiment [4] Group 2 - CME Group has gained approximately 19% year-to-date, outperforming the average Finance sector gain of 6.3% [4] - CME Group is part of the Securities and Exchanges industry, which has seen a year-to-date gain of about 16.1%, indicating better performance compared to its industry peers [6] - Another Finance stock, ACNB, has also outperformed the sector with a year-to-date return of 10.5% and a Zacks Rank of 2 (Buy) [5][6]

Group 1 - CME Group reached a 52-week high of $286.48 on May 7, with shares closing at $284.82, reflecting a 22% year-to-date gain, outperforming peers Cboe Global Markets and Intercontinental Exchange, which gained 19.9% and 18.5% respectively [1][2] - CME Group is the largest futures exchange globally, with a market capitalization of $102.6 billion and an average trading volume of 2.6 million shares over the last three months [2][3] - The company's diverse portfolio in emerging markets, electronic trading growth, and strong global presence are expected to drive future growth [3][24] Group 2 - CME shares are trading above both the 50-day and 200-day moving averages, indicating a bullish trend [7] - The price-to-earnings ratio of CME Group is 25.33X, higher than the industry average of 24.55X, indicating a premium valuation [11][13] - Analysts project a potential downside of 4.6% based on the average price target of $270.39 per share [15] Group 3 - The Zacks Consensus Estimate for 2025 earnings is $11.11, reflecting an 8.3% year-over-year increase, with revenues expected to rise to $6.5 billion [17][18] - Return on equity for CME was 14%, slightly above the industry average of 13.9%, while return on invested capital (ROIC) was around 10% over the last few years, but only 0.6% in the trailing 12 months [21][22] - CME Group benefits from heightened market volatility, which increases trading activity and transaction fees, contributing significantly to revenue [24] Group 4 - The company is experiencing rising electronic trading activity and increased interest in crypto assets, positioning it well for future growth [25][29] - CME has a strong capital base supporting initiatives to expand its market data business and product range [27] - Despite concentration risk in Interest Rate and Equity products, CME's global presence and product portfolio are expected to drive growth [28][30]

Financial Data and Key Metrics Changes - In 2024, CME Group achieved record revenue of $6.1 billion, a 10% increase compared to 2023, driven by strong average daily volume (ADV) of 26.5 million contracts per day, up 9% from the previous year [17][18] - Adjusted operating income for 2024 was $4.2 billion, reflecting a 12% year-over-year increase, with an adjusted operating margin of 68.3% [17] - The company reported adjusted net income of $3.7 billion, up 10% from 2023, and diluted earnings per share (EPS) of $10.26, the highest in its history [18] - For Q1 2025, CME Group's ADV reached 29.8 million contracts per day, setting a new record, with revenue surpassing $1.6 billion, a 10% increase year-over-year [19] Business Line Data and Key Metrics Changes - CME Group saw annual ADV records across its interest rate, foreign exchange, metals, and agricultural complexes in 2024 [17] - The company reported a year-to-date ADV of 31 million contracts per day in 2025, an 18% increase from the same period in 2024, with growth across all six asset classes [17] Market Data and Key Metrics Changes - CME Group's market position remains strong, with 99.99% of the business in SOFR contracts, despite competition from new exchanges like FMX, which has negligible trading volume [35][36] - The company continues to create significant efficiencies for clients, generating approximately $24 billion in daily savings in interest rates alone [36] Company Strategy and Development Direction - CME Group emphasizes its commitment to providing risk management tools and growing earnings for shareholders, focusing on operational efficiencies and client value propositions [28][36] - The company has a flexible capital return policy, including a quarterly dividend of $1.25 per share, up 9% from the previous year, and a share repurchase program of up to $3 billion [19][20] Management's Comments on Operating Environment and Future Outlook - Management highlighted that 2024 was the best year in CME Group's history, driven by global market participants seeking stability amid economic uncertainty [16] - The company remains optimistic about its future, with strong performance continuing into 2025 and a robust capital return strategy in place [21][20] Other Important Information - CME Group has returned over $28 billion to shareholders since adopting its variable dividend policy in 2012, including $3.8 billion in the last year [20] - The company plans to align its annual variable dividend timing with the Q1 regular dividend payment starting in 2026 [19] Q&A Session Summary Question: Impact of Passive Mutual Funds on Corporate Governance - A shareholder raised concerns about the growing ownership concentration of passive index funds and its implications for long-term corporate planning [24][25] - Management responded that they do not see inherent conflicts of interest and focus on providing risk management tools and growing earnings for shareholders [26][28] Question: Competition from New Exchanges - A shareholder inquired about the competition from FMX and its impact on CME Group [35] - Management noted that FMX's trading volume is minimal and emphasized CME's strong market position and efficiency in risk management [36] Question: Future Tax Proposals in Chicago - A shareholder asked about potential future tax proposals affecting trading [40] - Management clarified that the city of Chicago lacks the legal authority to impose such taxes, and state officials have opposed any transaction taxes on exchanges [41] Question: Status of Ongoing Litigation - A shareholder inquired about the status of a lawsuit involving the company [41] - Management indicated that the litigation is ongoing, with a court date set for July 7, and expressed confidence in their position [42]

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure within its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, compared to $10-$30 for standard bank wires [7] Market Trends - XRP is gaining traction among global institutions, with CME Group set to launch cash-settled XRP futures in May 2025 to meet institutional demand [6] - Mastercard has identified XRP as a bridge currency for cross-border payments, highlighting its efficiency and cost-effectiveness [7] Company Overview - Wellgistics Health operates across pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription hub services and aims to eliminate friction in the supply chain, enhancing reimbursement processes and creating transparent pathways [10]

Core Insights - Wellgistics Health, Inc. is launching an initiative to utilize XRP as a treasury reserve and real-time payments infrastructure, aiming to be among the first publicly traded healthcare companies to do so [1][3] - The initiative is backed by a $50 million Equity Line of Credit (ELOC) to enhance liquidity and financial infrastructure across its healthcare network [2] Company Strategy - The company aims to disrupt traditional healthcare systems by connecting manufacturers directly to pharmacies and patients, thereby increasing speed, liquidity, and transparency [3] - Wellgistics Health believes that the future of healthcare will favor companies with efficient platforms rather than those with large physical infrastructures [3] XRP Integration Benefits - The integration of XRP is expected to facilitate faster vendor payments, performance-based rebates, and liquidity tools for pharmacies and manufacturers [4] - XRP transactions settle in 3-5 seconds, significantly faster than traditional methods, and cost less than $0.0002 per transfer, enhancing operational efficiency [7] Market Positioning - Wellgistics Health is positioning itself to lead in the healthcare and fintech convergence by leveraging XRP, as evidenced by the growing institutional interest in XRP [6][8] - The company is focused on unlocking capital velocity and running operations more efficiently than its peers in the pharmaceutical infrastructure space [6] Industry Trends - XRP is gaining traction with major institutions, including the CME Group launching XRP futures and Mastercard identifying XRP as a bridge currency for cross-border payments [6][7] - Ripple's recent acquisitions and regulatory advancements further solidify XRP's role in the financial services landscape [8] Company Overview - Wellgistics Health operates in pharmaceutical distribution, prescription technology, and clinical fulfillment, connecting over 150 manufacturers to more than 6,000 independent pharmacies [9] - The company provides real-time prescription services and aims to streamline the medication supply chain by reducing friction and accelerating reimbursements [10]

Core Insights - CME Group reported an all-time monthly average daily volume (ADV) record of 35.9 million contracts in April 2025, representing a 36% increase year-over-year [1][2][3] Volume Growth by Product - Interest rate ADV grew 46% to 18.4 million contracts in April 2025 [2][4] - Equity index products reached a record monthly ADV of 9.7 million contracts [2][4] - Metals products also set a new record with an ADV of 1 million contracts [2][4] - SOFR futures achieved a monthly volume record of 6 million contracts [2] - Micro E-mini Nasdaq-100 futures reached 2.3 million contracts, while Micro E-mini S&P 500 futures hit 2 million contracts [2] - U.S. Treasury options recorded an ADV of 1.8 million contracts [2] International Volume Performance - International ADV reached 10.9 million contracts for the first time, driven by record EMEA ADV of 7.8 million contracts, Asia ADV of 2.6 million contracts, and Latin American ADV of 235,000 contracts [3] Detailed Product Highlights - Energy ADV was 3.3 million contracts, with WTI Crude Oil futures increasing 29% to 1.3 million contracts [4] - Agricultural ADV was 2.1 million contracts, with corn futures increasing 18% to 514,000 contracts [4] - Foreign Exchange ADV reached 1.3 million contracts, with Japanese Yen futures increasing 43% to 243,000 contracts [4] - Cryptocurrency ADV surged 129%, with Micro Bitcoin futures increasing 115% to 78,000 contracts [4] Additional Market Statistics - BrokerTec U.S. Repo average daily notional value (ADNV) increased 28% to a record $378 billion [7] - EBS Spot FX ADNV increased 46% to $89.3 billion [7] - Customer average collateral balances for cash collateral were $78.6 billion and for non-cash collateral were $173.7 billion [7]

Group 1 - CME Group is a member of the Finance sector, which includes 858 individual stocks and holds a Zacks Sector Rank of 2 [2] - CME Group currently has a Zacks Rank of 2 (Buy), with a 7.5% increase in the consensus estimate for full-year earnings over the past three months, indicating improved analyst sentiment [3] - Year-to-date, CME Group has gained approximately 19.3%, significantly outperforming the Finance sector average gain of 1.2% [4] Group 2 - CME Group belongs to the Securities and Exchanges industry, which consists of 7 companies and is ranked 8 in the Zacks Industry Rank, with an average gain of 12.4% this year [5] - Banco De Chile, another outperforming stock in the Finance sector, has increased by 30.2% year-to-date and has a Zacks Rank of 1 (Strong Buy) [4][5] - The Banks - Foreign industry, which includes Banco De Chile, has 66 stocks and is ranked 11, with a year-to-date gain of 14.7% [6]

Group 1 - CME Group is initiated with a Strong Buy rating and a price target of $332.96, highlighting its position as a global leader in futures and options trading [1] - The company operates in an institutionalized arena where trillions in futures and options are traded, routed, and cleared daily, emphasizing its critical role in the financial markets [1] - Moretus Research focuses on identifying companies with durable business models and mispriced cash flow potential, applying a structured framework for investment analysis [1] Group 2 - Moretus Research combines rigorous fundamental analysis with a judgment-driven process, aiming to provide clarity and actionable insights for serious investors [1] - The research emphasizes comparability, simplicity, and relevance in valuation, tailored to each company's business model and capital structure [1] - The coverage tends to favor underappreciated companies undergoing structural changes or temporary dislocations, where disciplined analysis can lead to asymmetric returns [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________ FORM 10-Q _________________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 - OR - ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n ...